Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "Glenmark-Pharmaceuticals"

87 News Found

Glenmark receives ANDA approval for treatment of acne
Drug Approval | September 21, 2021

Glenmark receives ANDA approval for treatment of acne

Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%


Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment
News | September 15, 2021

Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment

These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients


Glenmark signs agreement with SaNOtize to manufacture NONS
News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.


Glenmark Life Sciences IPO to open on July 27, 2021
News | July 26, 2021

Glenmark Life Sciences IPO to open on July 27, 2021

The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration


Glenmark receives ANDA tentative approval for Nintedanib Capsules
News | June 26, 2021

Glenmark receives ANDA tentative approval for Nintedanib Capsules

According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion


Glenmark receives ANDA approval for inhalation solution
News | June 24, 2021

Glenmark receives ANDA approval for inhalation solution

Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina


Glenmark's interim data from PMS Study on Favipiravir released
News | June 09, 2021

Glenmark's interim data from PMS Study on Favipiravir released

The study was conducted in patients with mild to moderate COVID-19


Glenmark receives ANDA approval for theophylline extended-release tablets
News | June 07, 2021

Glenmark receives ANDA approval for theophylline extended-release tablets

Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets


Glenmark Q4 FY 2020-21 revenue grows 3.3%; Net profit up 6.2%
News | May 29, 2021

Glenmark Q4 FY 2020-21 revenue grows 3.3%; Net profit up 6.2%

For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period


Glenmark receives ANDA approval for Icatibant Injection
News | May 25, 2021

Glenmark receives ANDA approval for Icatibant Injection

This marks Glenmark's first synthetic decapeptide injectable approval